Integra LifeSciences Holdings Corporation
IART
$15.10
-$0.02-0.13%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.64B | 1.64B | 1.64B | 1.62B | 1.62B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.64B | 1.64B | 1.64B | 1.62B | 1.62B |
| Cost of Revenue | 711.92M | 715.93M | 698.35M | 688.91M | 669.89M |
| Gross Profit | 932.59M | 919.31M | 944.62M | 932.83M | 954.41M |
| SG&A Expenses | 671.08M | 665.47M | 670.48M | 668.48M | 673.13M |
| Depreciation & Amortization | 15.03M | 14.95M | 14.90M | 14.93M | 14.89M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.48B | 1.48B | 1.47B | 1.46B | 1.45B |
| Operating Income | 167.46M | 158.15M | 172.96M | 158.20M | 172.70M |
| Income Before Tax | -535.88M | -563.50M | -545.27M | -558.81M | -43.04M |
| Income Tax Expenses | -40.08M | -47.03M | -49.94M | -58.18M | -14.09M |
| Earnings from Continuing Operations | -495.80 | -516.47 | -495.34 | -500.63 | -28.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -495.80M | -516.47M | -495.34M | -500.63M | -28.96M |
| EBIT | 167.46M | 158.15M | 172.96M | 158.20M | 172.70M |
| EBITDA | 320.53M | 309.98M | 331.05M | 313.73M | 320.21M |
| EPS Basic | -6.46 | -6.74 | -6.46 | -6.53 | -0.38 |
| Normalized Basic EPS | 0.81 | 0.73 | 0.90 | 0.83 | 0.99 |
| EPS Diluted | -6.47 | -6.74 | -6.46 | -6.53 | -0.38 |
| Normalized Diluted EPS | 0.81 | 0.73 | 0.90 | 0.83 | 0.99 |
| Average Basic Shares Outstanding | 307.18M | 306.69M | 306.33M | 306.03M | 306.74M |
| Average Diluted Shares Outstanding | 307.18M | 306.69M | 306.33M | 306.03M | 306.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |